Natasha completed her PhD and subsequently a Post-Doc at the Bioprocessing Technology Institute, A*STAR (Singapore), where she gained extensive knowledge and expertise in the area of protein glycosylation.
She then relocated to Melbourne where she joined CSL Research. Her work was focused on protein design and production for early-stage drug discovery and development. Subsequently, she joined Exopharm where she was involved in establishing a platform for the large-scale production of genetically modified exosomes.
As a Quality Assurance Specialist with the Burnet Vaccine Initiative, her responsibilities include implementing a Quality Management System that is tailored to the requirements of the vaccine development industry and regulatory agencies.
- 2022-2023: Senior Research Scientist, Exopharm, Australia
- 2018-2022: Research Scientist, CSL, Australia
- 2012-2017: PostDoctoral Scientist, Bioprocessing Technology Institute; A*STAR, Singapore
- 2012: Doctor of Philosophy (PhD) in Biochemistry, National University of Singapore